Cargando…

Tumor neoantigens: from basic research to clinical applications

Tumor neoantigen is the truly foreign protein and entirely absent from normal human organs/tissues. It could be specifically recognized by neoantigen-specific T cell receptors (TCRs) in the context of major histocompatibility complexes (MHCs) molecules. Emerging evidence has suggested that neoantige...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Tao, Shi, Tao, Zhang, Henghui, Hu, Jie, Song, Yuanlin, Wei, Jia, Ren, Shengxiang, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731555/
https://www.ncbi.nlm.nih.gov/pubmed/31492199
http://dx.doi.org/10.1186/s13045-019-0787-5
_version_ 1783449691816460288
author Jiang, Tao
Shi, Tao
Zhang, Henghui
Hu, Jie
Song, Yuanlin
Wei, Jia
Ren, Shengxiang
Zhou, Caicun
author_facet Jiang, Tao
Shi, Tao
Zhang, Henghui
Hu, Jie
Song, Yuanlin
Wei, Jia
Ren, Shengxiang
Zhou, Caicun
author_sort Jiang, Tao
collection PubMed
description Tumor neoantigen is the truly foreign protein and entirely absent from normal human organs/tissues. It could be specifically recognized by neoantigen-specific T cell receptors (TCRs) in the context of major histocompatibility complexes (MHCs) molecules. Emerging evidence has suggested that neoantigens play a critical role in tumor-specific T cell-mediated antitumor immune response and successful cancer immunotherapies. From a theoretical perspective, neoantigen is an ideal immunotherapy target because they are distinguished from germline and could be recognized as non-self by the host immune system. Neoantigen-based therapeutic personalized vaccines and adoptive T cell transfer have shown promising preliminary results. Furthermore, recent studies suggested the significant role of neoantigen in immune escape, immunoediting, and sensitivity to immune checkpoint inhibitors. In this review, we systematically summarize the recent advances of understanding and identification of tumor-specific neoantigens and its role on current cancer immunotherapies. We also discuss the ongoing development of strategies based on neoantigens and its future clinical applications.
format Online
Article
Text
id pubmed-6731555
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67315552019-09-12 Tumor neoantigens: from basic research to clinical applications Jiang, Tao Shi, Tao Zhang, Henghui Hu, Jie Song, Yuanlin Wei, Jia Ren, Shengxiang Zhou, Caicun J Hematol Oncol Review Tumor neoantigen is the truly foreign protein and entirely absent from normal human organs/tissues. It could be specifically recognized by neoantigen-specific T cell receptors (TCRs) in the context of major histocompatibility complexes (MHCs) molecules. Emerging evidence has suggested that neoantigens play a critical role in tumor-specific T cell-mediated antitumor immune response and successful cancer immunotherapies. From a theoretical perspective, neoantigen is an ideal immunotherapy target because they are distinguished from germline and could be recognized as non-self by the host immune system. Neoantigen-based therapeutic personalized vaccines and adoptive T cell transfer have shown promising preliminary results. Furthermore, recent studies suggested the significant role of neoantigen in immune escape, immunoediting, and sensitivity to immune checkpoint inhibitors. In this review, we systematically summarize the recent advances of understanding and identification of tumor-specific neoantigens and its role on current cancer immunotherapies. We also discuss the ongoing development of strategies based on neoantigens and its future clinical applications. BioMed Central 2019-09-06 /pmc/articles/PMC6731555/ /pubmed/31492199 http://dx.doi.org/10.1186/s13045-019-0787-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Jiang, Tao
Shi, Tao
Zhang, Henghui
Hu, Jie
Song, Yuanlin
Wei, Jia
Ren, Shengxiang
Zhou, Caicun
Tumor neoantigens: from basic research to clinical applications
title Tumor neoantigens: from basic research to clinical applications
title_full Tumor neoantigens: from basic research to clinical applications
title_fullStr Tumor neoantigens: from basic research to clinical applications
title_full_unstemmed Tumor neoantigens: from basic research to clinical applications
title_short Tumor neoantigens: from basic research to clinical applications
title_sort tumor neoantigens: from basic research to clinical applications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731555/
https://www.ncbi.nlm.nih.gov/pubmed/31492199
http://dx.doi.org/10.1186/s13045-019-0787-5
work_keys_str_mv AT jiangtao tumorneoantigensfrombasicresearchtoclinicalapplications
AT shitao tumorneoantigensfrombasicresearchtoclinicalapplications
AT zhanghenghui tumorneoantigensfrombasicresearchtoclinicalapplications
AT hujie tumorneoantigensfrombasicresearchtoclinicalapplications
AT songyuanlin tumorneoantigensfrombasicresearchtoclinicalapplications
AT weijia tumorneoantigensfrombasicresearchtoclinicalapplications
AT renshengxiang tumorneoantigensfrombasicresearchtoclinicalapplications
AT zhoucaicun tumorneoantigensfrombasicresearchtoclinicalapplications